Pharma channel feed – Endpoints News

Pharma channel feed

Merck unveils RSV antibody data, in bid to compete with AstraZeneca and Sanofi

6 months ago

Pfizer’s RSV vaccine has 90% efficacy against severe respiratory disease

6 months ago

Amicus stock jumps after resolution of Galafold patent litigation against Teva

6 months ago

Intercept's liver disease drug faces full approval delay following negative adcomm

6 months ago

FDA delays colorectal cancer decision for Amgen's Lumakras, a setback in race with Bristol Myers

6 months ago

FDA expands label for Avadel's narcolepsy drug into children

6 months ago

FDA approves AbbVie's 24-hour Parkinson's infusion therapy after two CRLs

6 months ago

Eisai to ask Australia to reconsider rejection of Alzheimer's drug Leqembi

6 months ago

Sanofi invests in new radioligand partner Orano Med, buying 16% stake for €300M

6 months ago

Bavarian Nordic's mpox vaccine was safe and spurred promising immune response in children

6 months ago

Compounding association to ask for clarity around tirzepatide's shortage status

6 months ago

Facing a critical week, Pfizer confronts an unsparing foe in Starboard

6 months ago

Q&A: Sanofi’s R&D head reflects on his first year, a post-Dupixent future, and finding an identity

6 months ago

Sacklers call opioid-related fraud claims 'utterly meritless'

7 months ago

GSK sues Moderna over mRNA vaccine patents, seeks 'reasonable royalty'

7 months ago

Jazz reports Phase 3 success for Zepzelca in first-line maintenance for small cell lung cancer

7 months ago

J&J’s medtech slump continues, improvements not expected until 2025

7 months ago

J&J trims pipeline, including two mid-stage neuroscience studies

7 months ago

Novo Nordisk files 18 lawsuits against GLP-1 compounders in 44 days

7 months ago

Eli Lilly reveals £279M investment in the UK through new government deal

7 months ago

Bausch + Lomb's stock rises following report of potential bid from private equity firms TPG and Blackstone

7 months ago

Two GSK trials with long-acting drug in chronic rhinosinusitis hit primary endpoints

7 months ago

Updated: Lundbeck makes $2.6B cash move for Longboard a month after starting Phase 3 in Dravet syndrome

7 months ago

FDA to reconsider removal of Lilly's GLP-1 drug from shortage list, a win for compounding pharmacies

7 months ago

First page Previous page 28 29 303132 33 34 Next page Last page